Publications

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Development and validation of an LC-MS/MS method for the quantification of the KRAS^G12C inhibitor divarasib.

18-07-2026

Pharmacological research

Daraxonrasib (RMC-6236) pharmacokinetics: impact of transporters and drug-metabolizing enzymes on a first-in-class pan-RAS molecular glue.

01-07-2026

Acta pharmacologica Sinica

Intestinal human carboxylesterase 2 (CES2) expression rescues drug metabolism and most metabolic syndrome phenotypes in global Ces2 cluster knockout mice.

01-03-2025

Toxicology and applied pharmacology

The role of drug efflux and uptake transporters in the plasma pharmacokinetics and tissue disposition of morphine and its main metabolites.

01-09-2024

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

ABCB1 attenuates brain exposure to the KRAS^G12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure.

01-06-2024

Clinical and translational science

Predictability of human exposure by human-CYP3A4-transgenic mouse models: A meta-analysis.

01-01-2024

Molecular pharmaceutics

Enhancement of the Oral Availability of Cabazitaxel Using the Cytochrome P450 3A (CYP3A) Inhibitor Ritonavir in Mice.

01-05-2023

Biomedical chromatography : BMC

Bioanalytical assay for the quantification of the tyrosine kinase inhibitor EAI045 and its major metabolite PIA in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

01-11-2022

Pharmacology research & perspectives

No relation between docetaxel administration route and high-grade diarrhea incidence.

01-08-2020

International journal of pharmaceutics

Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice.

15-05-2020

Cellular and molecular gastroenterology and hepatology

Inhibition of Hepatic Bile Acid Uptake by Myrcludex B Promotes Glucagon-Like Peptide-1 Release and Reduces Obesity.

25-04-2020

International journal of cancer

P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib.

15-03-2020

Cancer chemotherapy and pharmacology

Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes.

01-09-2019

Archives of toxicology

ABC transporters Mdr1a/1b, Bcrp1, Mrp2 and Mrp3 determine the sensitivity to PhIP/DSS-induced colon carcinogenesis and inflammation.

01-03-2019

Toxicology and applied pharmacology

Ochratoxin A transport by the human breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), and organic anion-transporting polypeptides 1A2, 1B1 and 2B1.

15-08-2017

Molecular pharmaceutics

Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo.

07-12-2015

Drug metabolism and disposition: the biological fate of chemicals

Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins.

01-08-2014

British journal of cancer

Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation.

27-05-2014

Clinical pharmacology and therapeutics

Hepatocyte hopping of OATP1B substrates contributes to efficient hepatic detoxification.

01-11-2012

Journal of clinical pharmacology

From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies.

01-03-2012

The Journal of clinical investigation

Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs.

01-08-2010

Molecular cancer therapeutics

Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation.

01-02-2010

Cancer research

Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.

01-12-2009

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry.

15-08-2009

Drug metabolism and disposition: the biological fate of chemicals

Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1).

01-02-2009

FASEB journal : official publication of the Federation of American Societies for Experimental Biology

Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver.

01-01-2009

Drug metabolism and disposition: the biological fate of chemicals

Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone.

01-01-2009

Molecular and cellular biology

Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk.

01-02-2007

Clinical cancer research : an official journal of the American Association for Cancer Research

Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.

15-10-2006

Carcinogenesis

Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk.

01-01-2006

Cancer research

Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.

15-08-2004

Cancer research

The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.

01-10-2003

Cancer research

A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance.

15-04-2002

Key Publication

Proceedings of the National Academy of Sciences of the United States of America

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

04-03-1997

FEBS letters

The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice.

14-11-1994

Cell

Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease.

05-11-1993

Cancer research

Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies.

15-05-1991

Development and validation of an LC-MS/MS method for the quantification of the KRASG12C inhibitor divarasib.

Daraxonrasib (RMC-6236) pharmacokinetics: impact of transporters and drug-metabolizing enzymes on a first-in-class pan-RAS molecular glue.

Intestinal human carboxylesterase 2 (CES2) expression rescues drug metabolism and most metabolic syndrome phenotypes in global Ces2 cluster knockout mice.

The role of drug efflux and uptake transporters in the plasma pharmacokinetics and tissue disposition of morphine and its main metabolites.

ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure.

Predictability of human exposure by human-CYP3A4-transgenic mouse models: A meta-analysis.

Enhancement of the Oral Availability of Cabazitaxel Using the Cytochrome P450 3A (CYP3A) Inhibitor Ritonavir in Mice.

Bioanalytical assay for the quantification of the tyrosine kinase inhibitor EAI045 and its major metabolite PIA in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

No relation between docetaxel administration route and high-grade diarrhea incidence.

Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice.

Inhibition of Hepatic Bile Acid Uptake by Myrcludex B Promotes Glucagon-Like Peptide-1 Release and Reduces Obesity.

P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib.

Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes.

ABC transporters Mdr1a/1b, Bcrp1, Mrp2 and Mrp3 determine the sensitivity to PhIP/DSS-induced colon carcinogenesis and inflammation.

Ochratoxin A transport by the human breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), and organic anion-transporting polypeptides 1A2, 1B1 and 2B1.

Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo.

Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins.

Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation.

Hepatocyte hopping of OATP1B substrates contributes to efficient hepatic detoxification.

From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies.

Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs.

Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation.

Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.

Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry.

Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1).

Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver.

Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone.

Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk.

Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.

Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk.

Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.

The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.

A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance.

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice.

Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease.

Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies.

This site uses cookies

Development and validation of an LC-MS/MS method for the quantification of the KRAS^G12C inhibitor divarasib.

ABCB1 attenuates brain exposure to the KRAS^G12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure.